Abstract：
BACKGROUND: To determine the effectiveness of bone marrow-derived mesenchymal stem cell therapy on visual acuity and visual field in patients with retinitis pigmentosa.
OBJECTIVE: Stem cell treatment in retinitis pigmentosa provides improvement in visual acuity and visual field.
METHODS: Forty-seven eyes of 27 patients diagnosed with retinitis pigmentosa were included in our study. Allogeneic bone marrow-derived mesenchymal stem cells were administered by deep subtenon injection. Complete routine ophthalmological examinations, optical coherence tomography (Zeiss, Cirrus HD-OCT) measurements, and visual field (Humphrey perimetry, 30-2) tests were performed on all patients before the treatment and on the 1st, 3rd, and 6th month after treatment. The best corrected visual acuities of the patients were determined by the Snellen chart and converted to logMAR. Visual evoked potential (VEP) and electroretinogram (ERG) examinations of the patients before the treatment and on the 6th month after the treatment were performed (Metrovision) data were compared.
RESULTS: Visual acuities were 0.74 ± 0.49 logMAR before treatment and 0.61 ± 0.46 logMAR after treatment. Visual acuity had a statistically significant increase (p < 0.001). The visual field deviation was found to be -27.16 ± 5.77 dB before treatment and -26.59 ± 5.96 dB after treatment (p = 0.005). The ganglion cell layer was 46.26 ± 12.87 μm before treatment and 52.47 ± 12.26 μm after treatment (p = 0.003). There was a significant improvement in Pattern VEP 120º P100 amplitude compared to that before the treatment (4.43 ± 2.42 μV) and that after the treatment (5.09 ± 2.86 μV) (p = 0.013). ERG latency measurements were 18.33 ± 15.39 μV before treatment and 20.87 ± 18.64 μV after treatment for scotopic 0.01 (p = 0.02). ERG latency measurements for scotopic 3.0 were 20.75 ± 26.31 μV before treatment and 23.10 ± 28.60 μV after treatment (p = 0.014).
CONCLUSIONS: Retinitis pigmentosa is a progressive, inherited disease that can result in severe vision loss. In retinitis pigmentosa, the application of bone marrow-derived mesenchymal stem cells by deep subtenon injection has positive effects on visual function. No systemic or ophthalmic side effects were detected in the patients during the 6-month follow-up period.
OBJECTIVE: Stem cell treatment in retinitis pigmentosa provides improvement in visual acuity and visual field.
METHODS: Forty-seven eyes of 27 patients diagnosed with retinitis pigmentosa were included in our study. Allogeneic bone marrow-derived mesenchymal stem cells were administered by deep subtenon injection. Complete routine ophthalmological examinations, optical coherence tomography (Zeiss, Cirrus HD-OCT) measurements, and visual field (Humphrey perimetry, 30-2) tests were performed on all patients before the treatment and on the 1st, 3rd, and 6th month after treatment. The best corrected visual acuities of the patients were determined by the Snellen chart and converted to logMAR. Visual evoked potential (VEP) and electroretinogram (ERG) examinations of the patients before the treatment and on the 6th month after the treatment were performed (Metrovision) data were compared.
RESULTS: Visual acuities were 0.74 ± 0.49 logMAR before treatment and 0.61 ± 0.46 logMAR after treatment. Visual acuity had a statistically significant increase (p < 0.001). The visual field deviation was found to be -27.16 ± 5.77 dB before treatment and -26.59 ± 5.96 dB after treatment (p = 0.005). The ganglion cell layer was 46.26 ± 12.87 μm before treatment and 52.47 ± 12.26 μm after treatment (p = 0.003). There was a significant improvement in Pattern VEP 120º P100 amplitude compared to that before the treatment (4.43 ± 2.42 μV) and that after the treatment (5.09 ± 2.86 μV) (p = 0.013). ERG latency measurements were 18.33 ± 15.39 μV before treatment and 20.87 ± 18.64 μV after treatment for scotopic 0.01 (p = 0.02). ERG latency measurements for scotopic 3.0 were 20.75 ± 26.31 μV before treatment and 23.10 ± 28.60 μV after treatment (p = 0.014).
CONCLUSIONS: Retinitis pigmentosa is a progressive, inherited disease that can result in severe vision loss. In retinitis pigmentosa, the application of bone marrow-derived mesenchymal stem cells by deep subtenon injection has positive effects on visual function. No systemic or ophthalmic side effects were detected in the patients during the 6-month follow-up period.
摘要：
背景：为了确定骨髓间充质干细胞治疗对色素性视网膜炎患者视力和视野的有效性。
目的：干细胞治疗视网膜色素变性可改善视力和视野。
方法：我们的研究包括27例诊断为色素性视网膜炎的47只眼。同种异体骨髓间充质干细胞通过深层皮下注射给药。完成常规眼科检查，光学相干层析成像(蔡司，CirrusHD-OCT)测量，和视野(汉弗莱视野，30-2）在治疗前和1日对所有患者进行了测试，3rd,治疗后6个月。通过Snellen图确定患者的最佳矫正视力，并转换为logMAR。比较患者治疗前和治疗后第6个月的视觉诱发电位（VEP）和视网膜电图（ERG）检查（Metrovision）数据。
结果：治疗前视力为0.74±0.49logMAR，治疗后视力为0.61±0.46logMAR。视敏度有统计学显著的增加(p<0.001)。治疗前视野偏差为-27.16±5.77dB，治疗后为-26.59±5.96dB（p=0.005）。治疗前神经节细胞层为46.26±12.87μm，治疗后为52.47±12.26μm（p=0.003）。与治疗前（4.43±2.42μV）和治疗后（5.09±2.86μV）相比，模式VEP120ºP100振幅显着改善（p=0.013）。治疗前的ERG潜伏期测量值分别为18.33±15.39μV和治疗后的20.87±18.64μV（p=0.02）。暗位3.0的ERG潜伏期测量值在治疗前为20.75±26.31μV，治疗后为23.10±28.60μV（p=0.014）。
结论：视网膜色素变性是一种进行性，可导致严重视力丧失的遗传性疾病。在色素性视网膜炎中，应用骨髓间充质干细胞进行深膜注射对视功能有积极影响。在6个月的随访期内，患者未发现全身或眼科副作用。
目的：干细胞治疗视网膜色素变性可改善视力和视野。
方法：我们的研究包括27例诊断为色素性视网膜炎的47只眼。同种异体骨髓间充质干细胞通过深层皮下注射给药。完成常规眼科检查，光学相干层析成像(蔡司，CirrusHD-OCT)测量，和视野(汉弗莱视野，30-2）在治疗前和1日对所有患者进行了测试，3rd,治疗后6个月。通过Snellen图确定患者的最佳矫正视力，并转换为logMAR。比较患者治疗前和治疗后第6个月的视觉诱发电位（VEP）和视网膜电图（ERG）检查（Metrovision）数据。
结果：治疗前视力为0.74±0.49logMAR，治疗后视力为0.61±0.46logMAR。视敏度有统计学显著的增加(p<0.001)。治疗前视野偏差为-27.16±5.77dB，治疗后为-26.59±5.96dB（p=0.005）。治疗前神经节细胞层为46.26±12.87μm，治疗后为52.47±12.26μm（p=0.003）。与治疗前（4.43±2.42μV）和治疗后（5.09±2.86μV）相比，模式VEP120ºP100振幅显着改善（p=0.013）。治疗前的ERG潜伏期测量值分别为18.33±15.39μV和治疗后的20.87±18.64μV（p=0.02）。暗位3.0的ERG潜伏期测量值在治疗前为20.75±26.31μV，治疗后为23.10±28.60μV（p=0.014）。
结论：视网膜色素变性是一种进行性，可导致严重视力丧失的遗传性疾病。在色素性视网膜炎中，应用骨髓间充质干细胞进行深膜注射对视功能有积极影响。在6个月的随访期内，患者未发现全身或眼科副作用。
